Clinical trial
A Placebo-controlled Study to Investigate the Safety, and Pharmacokinetics of…
NCT00443170 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00443170 |
|---|---|
| Title | A Placebo-controlled Study to Investigate the Safety, and Pharmacokinetics of Oral GSK626616AC in Healthy Subjects |
| Official title | A Randomized, Blinded, Placebo-controlled Study to Investigate the Safety, and Pharmacokinetics of Single and Repeat Dose Escalation of the Oral YAK3/DYRK3 Inhibitor GSK626616AC in Healthy Subjects |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Healthy Subjects, Anaemia |
| Intervention type | Drug |
| Interventions | GSK626616, placebo, midazolam, omeprazole, caffeine, flurbiprofen, rosiglitazone |
| Enrollment | 90 |
| Start date | Nov 1, 2006 |
| First posted | Mar 5, 2007 |
| Last update posted | Mar 19, 2012 |
| Countries | Australia |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: